Sinopharm Group Co Ltd
F:X2S1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sinopharm Group Co Ltd
F:X2S1
|
CN |
|
Mesoblast Ltd
ASX:MSB
|
AU |
|
U
|
Universal Technical Institute Inc
F:UTI
|
US |
|
P
|
Proto Labs Inc
SWB:PRZ
|
US |
|
R
|
RH
SWB:RS1
|
US |
|
Bank Rakyat Indonesia (Persero) Tbk PT
IDX:BBRI
|
ID |
|
Bank Rakyat Indonesia (Persero) Tbk PT
F:BYRA
|
ID |
|
R
|
Redcare Pharmacy NV
DUS:RDC
|
NL |
|
Dufry AG
F:D2J
|
CH |
|
U
|
USANA Health Sciences Inc
SWB:USJ
|
US |
|
D
|
Devon Energy Corp
XMUN:DY6
|
US |
|
C
|
Crest Nicholson Holdings PLC
F:C38
|
UK |
|
Crocs Inc
NASDAQ:CROX
|
US |
Wall St Price Targets
X2S1 Price Targets Summary
Sinopharm Group Co Ltd
According to Wall Street analysts, the average 1-year price target for X2S1 is 11.57 EUR with a low forecast of 9.36 EUR and a high forecast of 15.44 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is X2S1's stock price target?
Price Target
11.57
EUR
According to Wall Street analysts, the average 1-year price target for X2S1 is 11.57 EUR with a low forecast of 9.36 EUR and a high forecast of 15.44 EUR.
What is the Revenue forecast for Sinopharm Group Co Ltd?
Projected CAGR
4%
Over the last 14 years, the compound annual growth rate for Revenue has been 13%. The projected CAGR for the next 3 years is 4%.
What is the Gross Profit forecast for Sinopharm Group Co Ltd?
Projected CAGR
9%
Over the last 14 years, the compound annual growth rate for Gross Profit has been 12%. The projected CAGR for the next 3 years is 9%.
What is the Operating Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
7%
Over the last 14 years, the compound annual growth rate for Operating Income has been 11%. The projected CAGR for the next 3 years is 7%.
What is the Pre-Tax Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
7%
Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 12%. The projected CAGR for the next 3 years is 7%.
What is the Net Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
7%
Over the last 14 years, the compound annual growth rate for Net Income has been 11%. The projected CAGR for the next 3 years is 7%.
